Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 2/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.44 |
| ▸ | HK1 | P19367 | 2/20 | 0.41 |
| ▸ | HK2 | P52789 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26693098 | 0.79 | LGALS9 (0.40) | LGALS9LGALS1LGALS3LGALS7; LGALS7BHK1 | |
| SCHEMBL9655087 | 0.79 | CA12 (0.34) | LGALS9LGALS1LGALS3 | |
| SCHEMBL28854038 | 0.78 | TNF (0.42) | LGALS9LGALS1LGALS3LGALS7; LGALS7BALDH1A1 | |
| SCHEMBL28448346 | 0.78 | HK1 (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BHK1 | |
| SCHEMBL28448343 | 0.78 | HK1 (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BHK1 | |
| SCHEMBL29602084 | 0.77 | LGALS9 (0.33) | LGALS9LGALS1LGALS3LGALS7; LGALS7BHK1 | |
| SCHEMBL30843273 | 0.76 | LGALS9 (0.40) | LGALS9LGALS1LGALS3LGALS7; LGALS7BHK1 | |
| SCHEMBL29131407 | 0.73 | SLC5A2 (0.42) | — | |
| SCHEMBL9500829 | 0.73 | SLC5A2 (0.42) | — | |
| SCHEMBL9443607 | 0.72 | LGALS8 (0.44) | LGALS9LGALS1LGALS3LGALS7; LGALS7BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
| EP-3717463-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | Sanofi (FR) | 2020-10-07 | — | — | EP | disclosed |
| CN-111433193-A | Novel conjugates of agents and moieties capable of binding to glucose sensing proteins | 赛诺菲 | 2020-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | LGALS9 106/4885LGALS1 50/4885LGALS3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.